This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Münster, P. Articles by Daud, A. Search for Related Content PubMed PubMed Citation Articles by Münster, P. Articles by Daud, A. Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study

Pamela Münster, Douglas Marchion, Elona Bicaku, Morgen Schmitt, Ji Hyun Lee, Ronald DeConti, George Simon, Mayer Fishman, Susan Minton, Chris Garrett, Alberto Chiappori, Richard Lush, Daniel Sullivan, Adil Daud

From the Experimental Therapeutics, Breast Medical Oncology, and Cutaneous Oncology Programs, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL

Address reprint requests to Pamela Münster, MD, Division of Experimental Therapeutics, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, SRB-2, Tampa, FL 33612; e-mail: pamela.munster{at}moffitt.org

Purpose To determine the safety, toxicity, and maximum-tolerated dose of a sequence-specific combination of the histone deacetylase inhibitor (HDACi), valproic acid (VPA), and epirubicin in solid tumor malignancies and to define the clinical feasibility of VPA as an HDACi.

Patients and Methods Patients were treated with increasing doses of VPA (days 1 through 3) followed by epirubicin (day 3) in 3-week cycles. The study evaluated pharmacokinetic and pharmacodynamic end points, toxicities, and tumor response.

Results Forty-eight patients were enrolled, and 44 received at least one cycle of therapy. Patients (median age, 54 years; range, 39 to 78 years) received the following doses of VPA: 15, 30, 45, 60, 75, 90, 100, 120, 140, and 160 mg/kg/d. Dose-limiting toxicities were somnolence (n = 1), confusion (n = 3), and febrile neutropenia (n = 1). No exacerbation of epirubicin-related toxicities was observed. Partial responses were seen across different tumor types in nine patients (22%), and stable disease/minor responses were seen in 16 patients (39%), despite a median number of three prior regimens (range, zero to 10 prior regimens). Patients received a median number of four treatment cycles (range, one to 10 cycles), and treatment was stopped after reaching maximal epirubicin doses rather than progression in 13 (32%) of 41 patients patients. Total and free VPA plasma concentrations increased linearly with dose and correlated with histone acetylation in peripheral-blood mononuclear cells.

Conclusion The maximum-tolerated dose and recommended phase II dose was VPA 140 mg/kg/d for 48 hours followed by epirubicin 100 mg/m². Sustained plasma concentrations of VPA exceeding those required for in vitro synergy were achieved with acceptable toxicity. Noteworthy antitumor activity was observed in heavily pretreated patients and historically anthracycline-resistant tumors.

Supported by The Komen Foundation and by Grants No. PDF0402820 and NIH R21 CA105875. Study drug was supplied by Pfizer Global Research and Development, Ann Arbor, MI.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Addition of Histone Deacetylase Inhibitors in Combination Therapy
  Hetty E. Carraway and Steven D. Gore
  JCO 2007 25: 1955-1956 [Full Text]

This article has been cited by other articles:

				J. Fu, C.-J. Shao, F.-R. Chen, H.-K. Ng, and Z.-P. Chen Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines Neuro Oncology, October 15, 2009; (2009) nop005v1. [Abstract] [Full Text] [PDF]

				P Fritsche, B Seidler, S Schuler, A Schnieke, M Gottlicher, R M Schmid, D Saur, and G Schneider HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA Gut, October 1, 2009; 58(10): 1399 - 1409. [Abstract] [Full Text] [PDF]

				J. Hallas, S. Friis, L. Bjerrum, H. Stovring, S. F. Narverud, T. Heyerdahl, K. Gronbaek, and M. Andersen Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1714 - 1719. [Abstract] [Full Text] [PDF]

				J. Suzuki, Y.-Y. Chen, G. K. Scott, S. DeVries, K. Chin, C. C. Benz, F. M. Waldman, and E. S. Hwang Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression Clin. Cancer Res., May 1, 2009; 15(9): 3163 - 3171. [Abstract] [Full Text] [PDF]

				T. S. Cunneen, R. M. Conway, and M. C. Madigan In Vitro Effects of Histone Deacetylase Inhibitors and Mitomycin C on Tenon Capsule Fibroblasts and Conjunctival Melanoma Cells Arch Ophthalmol, April 1, 2009; 127(4): 414 - 420. [Abstract] [Full Text] [PDF]

				D. C. Marchion, E. Bicaku, J. G. Turner, M. L. Schmitt, D. R. Morelli, and P. N. Munster HDAC2 regulates chromatin plasticity and enhances DNA vulnerability Mol. Cancer Ther., April 1, 2009; 8(4): 794 - 801. [Abstract] [Full Text] [PDF]

				M. S.Q. Kortenhorst, S. Isharwal, P. J. van Diest, W. H. Chowdhury, C. Marlow, M. A. Carducci, R. Rodriguez, and R. W. Veltri Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo Mol. Cancer Ther., April 1, 2009; 8(4): 802 - 808. [Abstract] [Full Text] [PDF]

				P. Munster, D. Marchion, E. Bicaku, M. Lacevic, J. Kim, B. Centeno, A. Daud, A. Neuger, S. Minton, and D. Sullivan Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC Clin. Cancer Res., April 1, 2009; 15(7): 2488 - 2496. [Abstract] [Full Text] [PDF]

				A. I. Daud, J. Dawson, R. C. DeConti, E. Bicaku, D. Marchion, S. Bastien, F. A. Hausheer III, R. Lush, A. Neuger, D. M. Sullivan, et al. Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial Clin. Cancer Res., April 1, 2009; 15(7): 2479 - 2487. [Abstract] [Full Text] [PDF]

				A. Hadnagy, R. Beaulieu, and D. Balicki Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics Mol. Cancer Ther., April 1, 2008; 7(4): 740 - 748. [Abstract] [Full Text] [PDF]

				E. Bicaku, D. C. Marchion, M. L. Schmitt, and P. N. Munster Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling Cancer Res., March 1, 2008; 68(5): 1513 - 1519. [Abstract] [Full Text] [PDF]

				H. E. Carraway and S. D. Gore Addition of Histone Deacetylase Inhibitors in Combination Therapy J. Clin. Oncol., May 20, 2007; 25(15): 1955 - 1956. [Full Text] [PDF]